3 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 34548332 | EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. | 2022 Jan 1 | 3 |
| 2 | 35347108 | Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. | 2022 Mar 28 | 2 |
| 3 | 34077739 | Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. | 2021 Aug | 1 |